Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Factors contributing to the increase in profit included firm domestic sales of agrochemicals, higher export proceeds due to the weaker yen, improved terms of trade for methionine, increased demand for semiconductor process materials, improved terms of trade at Rabigh Refining and Petrochemical Company, gains arising from differences in inventory valuation following market price increases for synthetic resins and other products, and increased sales of Orgovyx and Gemtesa at Sumitomo Pharma. Factors contributing to the decline in profit included higher fixed costs in ICT & Mobility Solutions, product mix effects in Advanced Medical Solutions, and higher research and development expenses at Sumitomo Pharma, among others.
None. The notes regarding the going concern assumption state, “There are no applicable matters.”
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥578,199 million (YoY +9.9%) |
| Operating profit | ¥61,041 million (YoY +139.8%) |
| Ordinary income | ¥60,313 million (YoY +936.8%) |
| Profit attributable to owners of the parent | ¥40,782 million |
| Net income per share | ¥24.70 |
| Equity ratio | End of the current fiscal period 30.5 / End of previous period 29.6 |
| Total assets | ¥3,613,506 million |
| Net assets | ¥1,412,442 million |
| Cash flows from operating activities | ¥4,965 million |
| Cash flows from investing activities | ¥-49,232 million |
| Cash flows from financing activities | ¥55,569 million |
| Cash and cash equivalents at end of period | ¥223,197 million |
| Full-year earnings forecast | Net Sales ¥2,360,000 million (YoY +1.4%) / Operating profit ¥177,000 million (YoY +16.6%) / Ordinary income Not disclosed / Net income ¥70,000 million (YoY +14.9%) |
| Revision to Earnings Forecast | Interim period Net Sales To be determined → ¥1,170,000 million / Operating profit To be determined → ¥122,000 million / Ordinary income Not disclosed / Net income To be determined → ¥70,000 million / Full year No change |
| Annual Dividend Forecast | ¥13.5 → ¥16 |
| Segment revenue | Agro & Life Solutions ¥108,986 million / ICT & Mobility Solutions ¥148,573 million / Advanced Medical Solutions ¥10,447 million / Essential & Green Materials ¥170,192 million / Sumitomo Pharma ¥128,996 million |
| Segment profit | Agro & Life Solutions ¥9,631 million / ICT & Mobility Solutions ¥13,034 million / Advanced Medical Solutions ¥-1,938 million / Essential & Green Materials ¥27,224 million / Sumitomo Pharma ¥18,846 million |
| Depreciation and amortization | ¥29,117 million |
| Breakdown of extraordinary income (loss) | Non-recurring items Business structure improvement costs ¥-1,070 million, Other ¥-225 million |
| Disclosure regarding the going concern assumption | None. The notes regarding the going concern assumption state, “There are no applicable matters.” |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person For securities analysts and institutional investors |
| Issued Shares at Period-End | 1,657,914,399 |
| Treasury Shares at Period-End | 6,503,408 |
| Factors Behind Changes in Business Performance | Factors contributing to the increase in profit included firm domestic sales of agrochemicals, higher export proceeds due to the weaker yen, improved terms of trade for methionine, increased demand for semiconductor process materials, improved terms of trade at Rabigh Refining and Petrochemical Company, gains arising from differences in inventory valuation following market price increases for synthetic resins and other products, and increased sales of Orgovyx and Gemtesa at Sumitomo Pharma. Factors contributing to the decline in profit included higher fixed costs in ICT & Mobility Solutions, product mix effects in Advanced Medical Solutions, and higher research and development expenses at Sumitomo Pharma, among others. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Agro & Life Solutions, agrochemical sales remained firm, export proceeds increased due to the weaker yen, and terms of trade for methionine improved. In ICT & Mobility Solutions, demand for semiconductor process materials expanded. In Essential & Green Materials, terms of trade at an equity-method affiliate improved, and gains arose from differences in inventory valuation following market price increases for synthetic resins and other products. At Sumitomo Pharma, sales of Orgovyx and Gemtesa increased.